Bayer and its partner Regeneron Pharmaceuticals are collaborating on the global development of the drug for ‘wet’ AMD, central vein occlusion, diabetic macular oeda and myopic choroidal neovascularization.
The drug is claimed to require less-frequent injections once treatment is established – once every two months versus every month, following three loading doses.
Plenty of interest in RxSight’s Light Adjustable Lens at AUSCRS
RxSight believes Australian cataract surgeons are ready to embrace a technology that has already transformed refractive cataract surgery overseas, using...
